BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dore GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward). J Viral Hepat. 2014;21 Suppl 1:1-4. [PMID: 24713003 DOI: 10.1111/jvh.12253] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 9.4] [Reference Citation Analysis]
Number Citing Articles
1 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Doss W, Shiha G, Hassany M, Soliman R, Fouad R, Khairy M, Samir W, Hammad R, Kersey K, Jiang D, Doehle B, Knox SJ, Massetto B, Mchutchison JG, Esmat G. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Journal of Hepatology 2015;63:581-5. [DOI: 10.1016/j.jhep.2015.04.023] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 13.4] [Reference Citation Analysis]
3 Dore GJ, Hajarizadeh B. Elimination of Hepatitis C Virus in Australia. Infectious Disease Clinics of North America 2018;32:269-79. [DOI: 10.1016/j.idc.2018.02.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
4 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
5 Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat 2018;25:640-8. [DOI: 10.1111/jvh.12852] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
6 Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease: Ombitasvir/paritaprevir/ritonavir for CHC patients with CKD. Hepatol Res 2018;48:549-55. [DOI: 10.1111/hepr.13058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
7 Pourmarzi D, Hall L, Rahman T, Lim D, Fitzgerald G. Clinical effectiveness, cost-effectiveness and acceptability of community-based management of chronic hepatitis C: a mixed methods systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 2017;15:914-31. [DOI: 10.11124/jbisrir-2016-003103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
8 Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME. Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C. J Viral Hepat 2018;25:1089-98. [PMID: 29660212 DOI: 10.1111/jvh.12910] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
9 Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Front Cell Infect Microbiol. 2020;10:341. [PMID: 32850467 DOI: 10.3389/fcimb.2020.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Schaerer V, Haubitz S, Kovari H, Ledergerber B, Ambrosioni J, Cavassini M, Stoeckle M, Schmid P, Decosterd L, Aouri M, Böni J, Günthard HF, Furrer H, Metzner KJ, Fehr J, Rauch A; Swiss HIV Cohort Study. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Med 2015;16:599-607. [PMID: 26135140 DOI: 10.1111/hiv.12269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Boix R, Cano R, Gallego P, Vallejo F, Fernández-Cuenca R, Noguer I, Larrauri A. Hepatitis C hospitalizations in Spain, 2004-2013: a retrospective epidemiological study. BMC Health Serv Res 2017;17:461. [PMID: 28679375 DOI: 10.1186/s12913-017-2410-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden worldwide - filling the gaps. J Viral Hepat 2015;22 Suppl 1:1-5. [PMID: 25560838 DOI: 10.1111/jvh.12371] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
13 Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015;61:1523-32. [PMID: 25644279 DOI: 10.1002/hep.27705] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 9.6] [Reference Citation Analysis]
14 Takamizawa S, Yamada T, Kitamura K, Hiraoka E. Difficulty of acute hepatitis C diagnosis in a hospitalised patient. BMJ Case Rep 2018;11:e226907. [PMID: 30567115 DOI: 10.1136/bcr-2018-226907] [Reference Citation Analysis]
15 Gopalakrishnan S, Khatri A, Mensing S, Redman R, Menon R, Zha J. Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study. Adv Ther 2016;33:670-83. [PMID: 27084721 DOI: 10.1007/s12325-016-0320-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Nishimura N, Kaji K, Kitagawa K, Sawada Y, Furukawa M, Ozutsumi T, Fujinaga Y, Tsuji Y, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Fukui H, Yoshiji H. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. Int J Mol Sci 2021;22:6921. [PMID: 34203178 DOI: 10.3390/ijms22136921] [Reference Citation Analysis]
17 Biondi MJ, van Tilborg M, Smookler D, Heymann G, Aquino A, Perusini S, Mandel E, Kozak RA, Cherepanov V, Kowgier M, Hansen B, Goneau LW, Janssen HLA, Mazzulli T, Cloherty G, de Knegt RJ, Feld JJ. Hepatitis C Core-Antigen Testing from Dried Blood Spots. Viruses 2019;11:E830. [PMID: 31489933 DOI: 10.3390/v11090830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
18 Ghinea N, Lipworth W, Day R, Hill A, Dore GJ, Danta M. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. The Lancet 2017;389:1268-72. [DOI: 10.1016/s0140-6736(16)32051-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
19 Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22:833-838. [PMID: 27521803 DOI: 10.1016/j.cmi.2016.07.035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 14.2] [Reference Citation Analysis]
20 Martin NK, Vickerman P, Hickman M. How to eliminate HCV infection by antiviral treatment. J Hepatol 2017;67:5-6. [PMID: 28323120 DOI: 10.1016/j.jhep.2017.03.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
21 Muñoz-espinosa LE, Trujillo-trujillo ME, Martínez-macías RF, Panduro A, Rivas-estilla AM, Fierro NA, Silvera-linares AL, Torres-valadez R, Cordero-pérez P, González-aldaco K, Chen-lópez CY, José-abrego A, Zuñiga-noriega JR, Gutiérrez-ruiz MC, Roman S. Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico. Annals of Hepatology 2015;14:642-51. [DOI: 10.1016/s1665-2681(19)30758-6] [Cited by in Crossref: 10] [Article Influence: 1.4] [Reference Citation Analysis]
22 Behzadifar M, Gorji HA, Rezapour A, Bragazzi NL. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of Virus Eradication 2019;5:116-21. [DOI: 10.1016/s2055-6640(20)30053-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Llibre A, Shimakawa Y, Mottez E, Ainsworth S, Buivan TP, Firth R, Harrison E, Rosenberg AR, Meritet JF, Fontanet A, Castan P, Madejón A, Laverick M, Glass A, Viana R, Pol S, McClure CP, Irving WL, Miele G, Albert ML, Duffy D. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut 2018;67:2017-24. [PMID: 29615488 DOI: 10.1136/gutjnl-2017-315783] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
24 Alavi M, Grebely J, Hajarizadeh B, Amin J, Larney S, Law MG, George J, Degenhardt L, Dore GJ. Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infect Dis 2018;18:215. [PMID: 29743015 DOI: 10.1186/s12879-018-3110-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
25 Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio H, Hajarizadeh B, Hayes PC, Krajden M. Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: An international study. J Viral Hepat. 2018;25:473-481. [PMID: 29194861 DOI: 10.1111/jvh.12837] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
26 Marcellusi A, Viti R, Capone A, Mennini FS. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. PharmacoEcon Ital Res Artic 2014;16. [DOI: 10.1007/s40276-014-0023-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Borgia SM, Rowaiye A. Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada. Can J Gastroenterol Hepatol 2015;29:125-9. [PMID: 25855874 DOI: 10.1155/2015/591260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
28 Hutchinson SJ, Dillon JF, Fox R, McDonald SA, Innes HA, Weir A, McLeod A, Aspinall EJ, Palmateer NE, Taylor A, Munro A, Valerio H, Brown G, Goldberg DJ. Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience. Int J Drug Policy 2015;26:1041-9. [PMID: 26123893 DOI: 10.1016/j.drugpo.2015.05.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
29 Alavi M, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio HM, Hajarizadeh B, Hayes PC, Krajden M, Amin J, Law MG, George J, Goldberg DJ, Hutchinson SJ, Dore GJ. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. J Hepatol. 2018;68:393-401. [PMID: 29107152 DOI: 10.1016/j.jhep.2017.10.019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
30 Berenguer J. Eliminación del virus de la hepatitis C en España: un reto pendiente. Enfermedades Infecciosas y Microbiología Clínica 2018;36:323-4. [DOI: 10.1016/j.eimc.2018.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
31 Cheng ML, Abdel-hakeem MS, Cousineau SE, Grebely J, Marshall AD, Saeed S, Sagan SM, Shoukry NH, Feld JJ, Macparland SA. The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There”. CanLivJ 2018;1:139-52. [DOI: 10.3138/canlivj.2018-0018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Douglass CH, Pedrana A, Lazarus JV, 't Hoen EFM, Hammad R, Leite RB, Hill A, Hellard M. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med 2018;16:175. [PMID: 30296935 DOI: 10.1186/s12916-018-1162-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
33 Houri I, Horowitz N, Katchman H, Weksler Y, Miller O, Deutsch L, Shibolet O. Emergency department targeted screening for hepatitis C does not improve linkage to care. World J Gastroenterol 2020; 26(32): 4878-4888 [PMID: 32921964 DOI: 10.3748/wjg.v26.i32.4878] [Reference Citation Analysis]
34 Armstrong AR, Herrmann SE, Chassany O, Lalanne C, Da Silva MH, Galano E, Carrieri PM, Estellon V, Sogni P, Duracinsky M. The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus. BMC Infect Dis 2016;16:443. [PMID: 27553866 DOI: 10.1186/s12879-016-1771-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
35 Thurnheer MC, Schulz TR, Nguyen T, MacLachlan J, Sasadeusz J. Regional challenges: evaluation of a hepatitis outreach programme using transient elastography (FibroScan) in Victoria. Intern Med J 2016;46:273-81. [PMID: 26602052 DOI: 10.1111/imj.12963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
36 Elahi W, Syed AZ, Nasim F, Anwar A, Hashmi AA. Hepatitis B and C Infections in Patients With Prolonged Hemodialysis Secondary to Chronic Renal Failure. Cureus 2020;12:e10905. [PMID: 33194472 DOI: 10.7759/cureus.10905] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Paranaguá-Vezozzo DC, Andrade A, Mazo DFC, Nunes V, Guedes AL, Ragazzo TG, Moutinho R, Nacif LS, Ono SK, Alves VAF, Carrilho FJ. Concordance of non-invasive mechanical and serum tests for liver fibrosis evaluation in chronic hepatitis C. World J Hepatol 2017; 9(8): 436-442 [PMID: 28357031 DOI: 10.4254/wjh.v9.i8.436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
38 Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018;25 Suppl 1:6-17. [PMID: 29508946 DOI: 10.1111/jvh.12875] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
39 El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, Aly M, Mottawea W. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel) 2021;10:55. [PMID: 33451143 DOI: 10.3390/biology10010055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Hui YT, Wong GLH, Fung JYY, Chan HLY, Leung NWY, Liu SD, Liu K, Ma YK, But DYK, Mak WY, Chan JMC, Lai KB, Loo CK, Ng ACY, Lai MS, Chan CW, Lau JYL, Fan TTT, Hui AJ, Lam BCY, Cheung WI, Tsang OTY, Lam K, Lai LSW, Luk WF, Li MKK, Lao WC, Lam JTW, Tsang SWC, Kung KN, Chow WH, Tong RKN, Lui TKL, Shan EHS, Yuen MF, Wong VWS. Territory-wide population-based study of chronic hepatitis C infection and implications for hepatitis elimination in Hong Kong. Liver Int 2018;38:1911-9. [PMID: 29981176 DOI: 10.1111/liv.13926] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
41 Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry JR, Cheinquer H, Dusheiko G, Feld JJ, Gore C, Griswold MG, Hamid S, Hellard ME, Hou J, Howell J, Jia J, Kravchenko N, Lazarus JV, Lemoine M, Lesi OA, Maistat L, McMahon BJ, Razavi H, Roberts T, Simmons B, Sonderup MW, Spearman CW, Taylor BE, Thomas DL, Waked I, Ward JW, Wiktor SZ; Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019;4:135-184. [PMID: 30647010 DOI: 10.1016/s2468-1253(18)30270-x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 90.0] [Reference Citation Analysis]
42 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
43 Marshall AD, Grebely J, Dore GJ, Treloar C. ‘I didn’t want to let it go too far.’ The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy 2017;47:153-60. [DOI: 10.1016/j.drugpo.2017.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
44 Saludes V, Antuori A, Folch C, González N, Ibáñez N, Majó X, Colom J, Matas L, Casabona J, Martró E; HepCdetect II Study Group. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia. Int J Drug Policy 2019;74:236-45. [PMID: 31706159 DOI: 10.1016/j.drugpo.2019.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
45 Bretaña NA, Gray RR, Cunningham EB, Betz-Stablein B, Ribeiro R, Graw F, Luciani F, Lloyd AR. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study. Addiction 2020;115:901-13. [PMID: 31633853 DOI: 10.1111/add.14830] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
46 Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R, Lascar M, Bulman J, Reeves I, Palfreeman A, Foster GR, Ahmad K, Anderson J, Tong CY, Lattimore S. Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: the "Going Viral" campaign. HIV Med 2016;17:222-30. [PMID: 26919291 DOI: 10.1111/hiv.12364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
47 Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Clin Mol Hepatol 2019;25:42-51. [PMID: 30449076 DOI: 10.3350/cmh.2018.0029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
48 Treloar C, Jackson C, Gray R, Newland J, Wilson H, Saunders V, Johnson P, Brener L. Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments. Ethn Health 2016;21:39-57. [PMID: 25665723 DOI: 10.1080/13557858.2015.1004870] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
49 Kateera F, Walker TD, Mutesa L, Mutabazi V, Musabeyesu E, Mukabatsinda C, Bihizimana P, Kyamanywa P, Karenzi B, Orikiiriza JT. Hepatitis B and C seroprevalence among health care workers in a tertiary hospital in Rwanda. Trans R Soc Trop Med Hyg. 2015;109:203-208. [PMID: 25636951 DOI: 10.1093/trstmh/trv004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
50 Leumi S, Bigna JJ, Amougou MA, Aminde LN, Nyaga UF, Noubiap JJ. Global, regional, and national prevalence of hepatitis B infection in the general and key populations living with HIV: a systematic review and meta-analysis protocol. Syst Rev 2018;7:146. [PMID: 30261921 DOI: 10.1186/s13643-018-0815-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Khatri A, Mensing S, Podsadecki T, Awni W, Menon R, Dutta S. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients. Clin Drug Investig 2016;36:625-35. [PMID: 27153823 DOI: 10.1007/s40261-016-0407-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
52 Heffernan A, Barber E, Cook NA, Gomaa AI, Harley YX, Jones CR, Lim AG, Mohamed Z, Nayagam S, Ndow G. Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. Open Forum Infect Dis. 2017;5:ofx252. [PMID: 29354656 DOI: 10.1093/ofid/ofx252] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
53 Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service. PLoS One 2015;10:e0142770. [PMID: 26562516 DOI: 10.1371/journal.pone.0142770] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
54 Phelps CC, Walker CM, Honegger JR. Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses 2021;13:1351. [PMID: 34372558 DOI: 10.3390/v13071351] [Reference Citation Analysis]
55 Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824-1833. [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 15.5] [Reference Citation Analysis]
56 Aljumah AA, Abaalkhail F, Al-Ashgar H, Assiri A, Babatin M, Al Faleh F, Alghamdi A, Al-Hakeem R, Hashim A, Alqutub A, Razavi H, Sanai FM, Al-Swat K, Schmelzer J, Altraif I. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol 2016;22:269-81. [PMID: 27488321 DOI: 10.4103/1319-3767.187609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
57 Lin BM, White M, Glover A, Wamah GP, Trotti DL, Randall K, Alkire BC, Cheney ML, Parker G, Shrime MG. Barriers to Surgical Care and Health Outcomes: A Prospective Study on the Relation Between Wealth, Sex, and Postoperative Complications in the Republic of Congo. World J Surg 2017;41:14-23. [PMID: 27473131 DOI: 10.1007/s00268-016-3676-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
58 Milosevic I, Russo E, Vujovic A, Barac A, Stevanovic O, Gitto S, Amedei A. Microbiota and viral hepatitis: State of the art of a complex matter. World J Gastroenterol 2021; 27(33): 5488-5501 [PMID: 34588747 DOI: 10.3748/wjg.v27.i33.5488] [Reference Citation Analysis]
59 Mcdonald SA, Azzeri A, Shabaruddin FH, Dahlui M, Tan SS, Kamarulzaman A, Mohamed R. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040. Appl Health Econ Health Policy 2018;16:847-57. [DOI: 10.1007/s40258-018-0425-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
60 Ford N, Swan T, Beyer P, Hirnschall G, Easterbrook P, Wiktor S. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings. J Hepatol. 2014;61:S132-S138. [PMID: 25443341 DOI: 10.1016/j.jhep.2014.09.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
61 Romano J, Sims OT, Richman J, Guo Y, Matin T, Shoreibah M, Kommineni V, Venkata K, Massoud OI. Resolution of ascites and hepatic encephalopathy and absence of variceal bleeding in decompensated hepatitis C virus cirrhosis patients. JGH Open 2018;2:317-21. [PMID: 30619944 DOI: 10.1002/jgh3.12091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
62 Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H, Lacombe K, Matthews GV, Schultz M, Klein M, Hezode C, Mercade GE, Kho D, Petoumenos K, Marks P, Tatsch F, Dos Santos AGP, Gane E. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology 2020;72:431-40. [DOI: 10.1016/j.jhep.2019.10.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
63 Wandeler G, Schlauri M, Jaquier ME, Rohrbach J, Metzner KJ, Fehr J, Ambrosioni J, Cavassini M, Stöckle M, Schmid P, Bernasconi E, Keiser O, Salazar-Vizcaya L, Furrer H, Rauch A, Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Gorgievski M, Günthard H, Haerry D, Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A, Regenass S, Rickenbach M, Rudin C, Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S; Swiss HIV Cohort Study. Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. Open Forum Infect Dis 2015;2:ofv026. [PMID: 26034775 DOI: 10.1093/ofid/ofv026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
64 Butler K, Day C, Sutherland R, van Buskirk J, Breen C, Burns L, Larney S. Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. International Journal of Drug Policy 2017;47:102-6. [DOI: 10.1016/j.drugpo.2017.07.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
65 Taylor AL, Denniston MM, Klevens RM, McKnight-Eily LR, Jiles RB. Association of Hepatitis C Virus With Alcohol Use Among U.S. Adults: NHANES 2003-2010. Am J Prev Med 2016;51:206-15. [PMID: 27178884 DOI: 10.1016/j.amepre.2016.02.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
66 Orkin C, Jeffery-Smith A, Foster GR, Tong CY. Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women? BMJ Open 2016;6:e010661. [PMID: 27231001 DOI: 10.1136/bmjopen-2015-010661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
67 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]
68 Wade AJ, Veronese V, Hellard ME, Doyle JS. A systematic review of community based hepatitis C treatment. BMC Infect Dis 2016;16:202. [PMID: 27184661 DOI: 10.1186/s12879-016-1548-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
69 Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatol Res 2019;49:125-35. [PMID: 30307682 DOI: 10.1111/hepr.13256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
70 Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME. Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs. Clinical Infectious Diseases 2020;70:1900-6. [DOI: 10.1093/cid/ciz546] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
71 Marshall AD, Pawlotsky J, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat. Journal of Hepatology 2018;69:1188-96. [DOI: 10.1016/j.jhep.2018.06.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 13.3] [Reference Citation Analysis]
72 Rice CM, Saeed M. Hepatitis C: Treatment triumphs. Nature. 2014;510:43-44. [PMID: 24899301 DOI: 10.1038/510043a] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
73 Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME. Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial. Trials 2018;19:383. [PMID: 30012192 DOI: 10.1186/s13063-018-2768-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
74 Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 2020;95:84-9. [PMID: 32302766 DOI: 10.1016/j.ijid.2020.03.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland SA, Marshall A, Saeed S, Wilson J, Klein MB, Sagan SM. The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet-Remaining Challenges in Hepatitis C. Can J Gastroenterol Hepatol 2016;2016:7603526. [PMID: 27843889 DOI: 10.1155/2016/7603526] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]